PREVALENCE , IMPACT , AND ETIOLOGY OF RENAL INSUFFICIENCY IN LIVER TRANSPLANTATION Scope of the Problem and Impact on Outcomes

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group

  2012cited by this paper
• Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function

  2009cited by this paper
• Calcineurin inhibitor minimization protocols in liver transplantation

  2009cited by this paper
• Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting List

  2009cited by this paper
• Delayed Introduction of Reduced‐Dose Tacrolimus, and Renal Function in Liver Transplantation: The ‘ReSpECT' Study

  2009cited by this paper
• Management of chronic allograft nephropathy: a systematic review.

  2009influential reference
• Alefacept treatment for refractory chronic extensive GVHD

  2009cited by this paper
• Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis.

  2008cited by this paper
• Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients.

  2008cited by this paper
• Development of a risk stratification model for predicting acute renal failure in orthotopic liver transplantation recipients *

  2008cited by this paper
• Declining Outcomes in Simultaneous Liver-Kidney Transplantation in the MELD Era: Ineffective Usage of Renal Allografts

  2008cited by this paper
• Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK)

  2008cited by this paper
• Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients

  2008cited by this paper
• The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months.

  2008cited by this paper
• Primary Prophylaxis of Spontaneous Bacterial Peritonitis Delays Hepatorenal Syndrome and Improves Survival in Cirrhosis

  2008cited by this paper
• Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low‐dose calcineurin inhibitor regimens

  2008cited by this paper
• Prediction of survival after liver transplantation by pre-transplant parameters

  2008cited by this paper
• Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage.

  2008cited by this paper
• Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects

  2008cited by this paper
• The effect of aprotinin on outcome after coronary-artery bypass grafting.

  2008cited by this paper
• Calculating Life Years from Transplant (LYFT): Methods for Kidney and Kidney‐Pancreas Candidates

  2008cited by this paper
• Vasoconstrictor therapy for the hepatorenal syndrome.

  2008cited by this paper
• Reduced exposure to calcineurin inhibitors in renal transplantation.

  2008influential reference
• A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

  2008cited by this paper
• Chronic renal dysfunction following liver transplantation

  2008influential reference
• What's Next in the Pipeline

  2008influential reference
• Vasoactive drugs and acute kidney injury

  2008cited by this paper
• The hepatorenal syndrome.

  2008cited by this paper
• A RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TWO DIFFERENT SIROLIMUS (SRL) REGIMENS WITH TACROLIMUS (TAC) + MYCOPHENOLATE MOFETIL (MMF) IN DE NOVO RENAL ALLOGRAFT RECIPIENTS: PRELIMINARY 2-YEAR SAFETY RESULTS FROM THE ORION TRIAL: 444

  2008cited by this paper
• Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

  2008cited by this paper
• Terlipressin Improves Renal Function in Patients with Cirrhosis and Ascites without Hepatorenal Syndrome

  2008cited by this paper
• Kidney Allocation to Liver Transplant Candidates with Renal Failure of Undetermined Etiology: Role of Percutaneous Renal Biopsy

  2008cited by this paper
• Hemodynamic and metabolic efficacy of dopamine versus norepinephrine in a brain‐dead swine model

  2008cited by this paper
• Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study

  2008cited by this paper
• Development of Proteinuria After Switch to Sirolimus‐Based Immunosuppression in Long‐Term Cardiac Transplant Patients

  2008cited by this paper
• Humoral and cellular immune monitoring might be useful to identify liver transplant recipients at risk for development of infection

  2008cited by this paper
• Multiparameter Immune Profiling of Operational Tolerance in Liver Transplantation

  2007cited by this paper
• Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis.

  2007cited by this paper
• Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation.

  2007cited by this paper
• Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury

  2007cited by this paper
• Renal failure and bacterial infections in patients with cirrhosis: Epidemiology and clinical features

  2007cited by this paper
• A Phase I/II Randomized Open‐Label Multicenter Trial of Efalizumab, a Humanized Anti‐CD11a, Anti‐LFA‐1 in Renal Transplantation

  2007cited by this paper
• Short‐term induction therapy with anti‐thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation

  2007cited by this paper
• Long‐term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation

  2007cited by this paper
• Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.

  2007cited by this paper
• Lack of Benefit of Early Protocol Biopsies in Renal Transplant Patients Receiving TAC and MMF: A Randomized Study

  2007cited by this paper
• A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)‐based to sirolimus‐based immunosuppression in liver transplant recipients with impaired renal function

  2007cited by this paper
• Banff '05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (‘CAN’)

  2007cited by this paper
• New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone.

  2007cited by this paper
• Cirrhosis-induced defects in innate pulmonary defenses against Streptococcus pneumoniae

  2007cited by this paper
• Validation of a Liquid Chromatography-Mass Spectrometric Assay for Tacrolimus in Liver Biopsies After Hepatic Transplantation: Correlation With Histopathologic Staging of Rejection

  2007cited by this paper
• Acute Renal Disease, as Defined by the RIFLE Criteria, Post‐Liver Transplantation

  2007cited by this paper
• Acute renal dysfunction in liver diseases.

  2007cited by this paper
• Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation.

  2007cited by this paper
• Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis

  2007influential reference
• Simultaneous Liver–Kidney Transplantation: Evaluation to Decision Making

  2007cited by this paper
• Diagnosis and treatment of acute renal failure in patients with cirrhosis.

  2007cited by this paper
• Randomized Controlled Trial of Total Immunosuppression Withdrawal in Liver Transplant Recipients: Role of Ursodeoxycholic Acid

  2007cited by this paper
• Conversion to sirolimus‐based immunosuppression in maintenance liver transplantation patients

  2007cited by this paper
• Hepatorenal syndrome: A proposal for kidney after liver transplantation (KALT)

  2007cited by this paper
• Switch to 1.5 grams MMF monotherapy for CNI‐related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension

  2007cited by this paper
• Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials.

  2007cited by this paper
• Kidney Transplantation With Sirolimus and Mycophenolate Mofetil–Based Immunosuppression: 5-Year Results of a Randomized Prospective Trial Compared to Calcineurin Inhibitor Drugs

  2007cited by this paper
• [Abdominal compartment syndrome].

  2007cited by this paper
• Metaanalysis: Low-Dose Dopamine Increases Urine Output but Does Not Prevent Renal Dysfunction or DeathFriedrich JO, Adhikari N, Herridge MS, et al (St Michaeľs Hosp, Toronto; Sunnybrook and Women's College, Toronto; Toronto Gen Hosp; et al) Ann Intern Med 142:510–524, 2005§

  2006cited by this paper
• Effect of low central venous pressure and phlebotomy on blood product transfusion requirements during liver transplantations.

  2006cited by this paper
• The aetiology and pathogenesis of chronic allograft nephropathy.

  2006cited by this paper
• Brief Communication: Glomerulonephritis in Patients with Hepatitis C Cirrhosis Undergoing Liver Transplantation

  2006cited by this paper
• Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis.

  2006cited by this paper
• N-Acetylcysteine for the Prevention of Kidney Injury in Abdominal Aortic Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial

  2006cited by this paper
• Immunosuppression: Today, Tomorrow, and Withdrawal

  2006influential reference
• Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation

  2006cited by this paper
• A New Look at Blockade of T‐cell Costimulation: A Therapeutic Strategy for Long‐term Maintenance Immunosuppression

  2006cited by this paper
• Calcineurin Inhibitor Avoidance with Daclizumab, Mycophenolate Mofetil, and Prednisolone in DR-Matched de Novo Kidney Transplant Recipients

  2006cited by this paper
• Risk factors of acute renal failure after liver transplantation.

  2006cited by this paper
• Life expectancy of adult liver allograft recipients in the UK

  2006cited by this paper
• Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation

  2006cited by this paper
• Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients.

  2006cited by this paper
• Chronic Allograft Nephropathy: Current Concepts and Future Directions

  2006cited by this paper
• Long-term analysis of combined liver and kidney transplantation at a single center.

  2006cited by this paper
• Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.

  2006cited by this paper
• Liver and Kidney Transplantation for Polycystic Liver and Kidney-Renal Function and Outcome

  2006cited by this paper
• Continued Influence of Preoperative Renal Function on Outcome of Orthotopic Liver Transplant (OLTX) in the US: Where Will MELD Lead Us?

  2006cited by this paper
• High prevalence of renal dysfunction in long-term survivors after pediatric liver transplantation.

  2006cited by this paper
• Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway.

  2006cited by this paper
• Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction.

  2006cited by this paper
• Complete Avoidance of Calcineurin Inhibitors in Renal Transplantation: A Randomized Trial Comparing Sirolimus and Tacrolimus

  2006influential reference
• Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence.

  2006cited by this paper
• Costimulation Blockade With Belatacept in Renal Transplantation

  2006cited by this paper
• Post-transplantation proteinuria and sirolimus.

  2005cited by this paper
• Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing cabg surgery: a randomized controlled trial.

  2005cited by this paper
• Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low‐dose tacrolimus regimen vs. a standard‐dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized clinical trial

  2005cited by this paper
• Reduction of blood product transfusions during liver transplantation

  2005cited by this paper
• ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.

  2005cited by this paper
• Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.

  2005cited by this paper
• Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation

  2005cited by this paper
• Dopamine "renal dose" versus fenoldopam mesylate to prevent ischemia-reperfusion injury in renal transplantation.

  2005cited by this paper
• The Role of Donor Bone Marrow Infusions in Withdrawal of Immunosuppression in Adult Liver Allotransplantation

  2005cited by this paper
• LIVER FAILURE AND LIVER DISEASE

  2005cited by this paper
• Mycophenolate mofetil monotherapy in liver transplantation.

  2005cited by this paper

• A synthesis review of nature positive approaches and coexistence in the offshore wind industry

  2023cites this paper
• Care of the Liver Transplant Recipient

  2021cites this paper
• Interleukin-2 receptor antibody induction with early low dose tacrolimus preserves post-liver transplant renal function in at risk individuals

  2021cites this paper
• Care of the liver transplant patient.

  2014cites this paper
• Organ Allocation in Liver Transplantation: Ethics, Organ Supply, and Evidencebased Practice

  2012cites this paper
• Initial immunosuppression with or without basiliximab: a comparative study.

  2012cites this paper
• Management of Renal Disease in the Liver Transplant Candidate

  2012cites this paper
• Proteinuria Following Sirolimus Conversion is Associated With Deterioration of Kidney Function in Liver Transplant Recipients

  2012cites this paper